The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin was recently tested in a prospective randomized placebo-controlled study in a large group of patients with type 2 diabetes mellitus. The gene discussed is SLC5A2; the disease is diabetes mellitus.